Orchard Therapeutics Analyst Ratings
Orchard Therapeutics Analyst Ratings
While ratings are subjective and will change, the latest Orchard Therapeutics (ORTX) rating was a reiterated with a price target of $0.00 to $34.00. The current price Orchard Therapeutics (ORTX) is trading at is $5.17, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 557.64% | Oppenheimer | → $34 | Reiterates | Outperform → Outperform |
| 06/27/2023 | 190.14% | Cantor Fitzgerald | → $15 | Reiterates | Overweight → Overweight |
| 06/13/2023 | 557.64% | Oppenheimer | $37 → $34 | Maintains | Outperform |
| 03/28/2023 | 190.14% | Cantor Fitzgerald | $3 → $15 | Maintains | Overweight |
| 05/13/2022 | -22.63% | Barclays | $6 → $4 | Maintains | Overweight |
| 04/01/2022 | — | SMBC Nikko | Downgrades | Outperform → Neutral | |
| 03/31/2022 | — | Cowen & Co. | Downgrades | Outperform → Market Perform | |
| 11/16/2021 | — | JP Morgan | Downgrades | Neutral → Underweight | |
| 11/05/2021 | 151.45% | Oppenheimer | $15 → $13 | Maintains | Outperform |
| 08/18/2021 | — | JP Morgan | Downgrades | Overweight → Neutral | |
| 03/02/2021 | 190.14% | JP Morgan | $14 → $15 | Assumes | → Overweight |
| 01/07/2021 | 209.48% | Cantor Fitzgerald | → $16 | Initiates Coverage On | → Overweight |
| 04/01/2020 | 441.59% | Oppenheimer | $29 → $28 | Maintains | Outperform |
| 09/17/2019 | 499.61% | Guggenheim | → $31 | Initiates Coverage On | → Buy |
| 09/05/2019 | 306.19% | Barclays | → $21 | Initiates Coverage On | → Overweight |
| 08/30/2019 | 402.9% | Oppenheimer | → $26 | Initiates Coverage On | → Outperform |
| 12/17/2018 | 306.19% | Goldman Sachs | $18 → $21 | Upgrades | Neutral → Buy |
| 11/26/2018 | 422.24% | Cowen & Co. | → $27 | Initiates Coverage On | → Outperform |
| 11/26/2018 | 248.16% | Goldman Sachs | → $18 | Initiates Coverage On | → Neutral |
| 11/26/2018 | 383.56% | Wedbush | → $25 | Initiates Coverage On | → Outperform |
| 11/26/2018 | — | JP Morgan | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 08/09/2023 | 557.64% | 奧本海默 | →$34 | 重申 | 跑贏→跑贏大盤 |
| 2023年6月27日 | 190.14% | 康託·菲茨傑拉德 | →$15 | 重申 | 超重→超重 |
| 2023/06/13 | 557.64% | 奧本海默 | $37→$34 | 維護 | 跑贏大盤 |
| 03/28/2023 | 190.14% | 康託·菲茨傑拉德 | $3→$15 | 維護 | 超重 |
| 2022年05月13日 | -22.63% | 巴克萊 | $6→$4 | 維護 | 超重 |
| 04/01/2022 | - | SMBC日興 | 評級下調 | 跑贏→中性 | |
| 03/31/2022 | - | 考恩公司 | 評級下調 | 跑贏→市場表現 | |
| 2021年11月16日 | - | 摩根大通 | 評級下調 | 中性→減持 | |
| 2021年11月05日 | 151.45% | 奧本海默 | $15→$13 | 維護 | 跑贏大盤 |
| 2021/08/18 | - | 摩根大通 | 評級下調 | 超重→中性 | |
| 03/02/2021 | 190.14% | 摩根大通 | $14→$15 | 假設 | →超重 |
| 01/07/2021 | 209.48% | 康託·菲茨傑拉德 | →$16 | 開始承保 | →超重 |
| 04/01/2020 | 441.59% | 奧本海默 | $29→$28 | 維護 | 跑贏大盤 |
| 2019/09/17 | 499.61% | 古根海姆 | →$31 | 開始承保 | →購買 |
| 2019年05月09日 | 306.19% | 巴克萊 | →$21 | 開始承保 | →超重 |
| 2019年08月30日 | 402.9% | 奧本海默 | →$26 | 開始承保 | →跑贏大盤 |
| 2018年12月17日 | 306.19% | 高盛 | $18→$21 | 升級 | 中性→購買 |
| 2018年11月26日 | 422.24% | 考恩公司 | →$27 | 開始承保 | →跑贏大盤 |
| 2018年11月26日 | 248.16% | 高盛 | →$18 | 開始承保 | →中性 |
| 2018年11月26日 | 383.56% | 韋德布什 | →$25 | 開始承保 | →跑贏大盤 |
| 2018年11月26日 | - | 摩根大通 | 開始承保 | →超重 |
What is the target price for Orchard Therapeutics (ORTX)?
Orchard Treeutics(ORTX)的目標價格是多少？
The latest price target for Orchard Therapeutics (NASDAQ: ORTX) was reported by Oppenheimer on August 9, 2023. The analyst firm set a price target for $34.00 expecting ORTX to rise to within 12 months (a possible 557.64% upside). 4 analyst firms have reported ratings in the last year.
奧本海默於2023年8月9日報道了果園治療公司(納斯達克：ORTX)的最新目標價。這家分析公司將目標價定為34美元，預計ORTX將在12個月內上漲至(可能上漲557.64%)。去年有4家分析公司公佈了評級。
What is the most recent analyst rating for Orchard Therapeutics (ORTX)?
Orchard Treeutics(ORTX)的最新分析師評級是什麼？
The latest analyst rating for Orchard Therapeutics (NASDAQ: ORTX) was provided by Oppenheimer, and Orchard Therapeutics reiterated their outperform rating.
奧本海默公司提供了對果園治療公司(納斯達克代碼：ORTX)的最新分析師評級，果園治療公司重申了他們的表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for Orchard Therapeutics (ORTX)?
Orchard Treeutics(ORTX)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Orchard Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Orchard Therapeutics was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與Orchard Treeutics的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。Orchard Treeutics的上一次評級是在2023年8月9日提交的，所以你應該預計下一次評級將在2024年8月9日左右提供。
Is the Analyst Rating Orchard Therapeutics (ORTX) correct?
分析師對Orchard Treeutics(ORTX)的評級正確嗎？
While ratings are subjective and will change, the latest Orchard Therapeutics (ORTX) rating was a reiterated with a price target of $0.00 to $34.00. The current price Orchard Therapeutics (ORTX) is trading at is $5.17, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的果園治療公司(ORTX)評級被重申，目標價在0.00美元至34.00美元之間。果園治療公司(ORTX)目前的交易價格為5.17美元，在分析師的預測範圍內。